WHO And Gilead Sciences Attributed A Mistake To The Publication Of The Failure Of Clinical Trials Of Remdesivir

Table of contents:

WHO And Gilead Sciences Attributed A Mistake To The Publication Of The Failure Of Clinical Trials Of Remdesivir
WHO And Gilead Sciences Attributed A Mistake To The Publication Of The Failure Of Clinical Trials Of Remdesivir

Video: WHO And Gilead Sciences Attributed A Mistake To The Publication Of The Failure Of Clinical Trials Of Remdesivir

Отличия серверных жестких дисков от десктопных
Video: Gilead tells developments in clinical trials of Remdesivir against coronavirus 2023, February
Anonim

WHO and Gilead Sciences attributed a mistake to the publication of the failure of clinical trials of remdesivir

The results, indicating a failed clinical trial of the drug, which has high hopes for the treatment of COVID, previously appeared in the WHO database

WHO and Gilead Sciences attributed a mistake to the publication of the failure of clinical trials of remdesivir
WHO and Gilead Sciences attributed a mistake to the publication of the failure of clinical trials of remdesivir

Photo: Ivan Radic

It was reported that the study, which was conducted in China, involved 237 patients with COVID-19, 158 received remdesivir, 79 - placebo. One month later, 13.9% of patients taking the drug and 12.8% of patients in the placebo group died. The trials were stopped early due to side effects. From the results of clinical studies, it follows that the drug does not improve the condition of a patient with a new coronavirus infection and does not reduce the presence of pathogenic microorganisms in the blood of an infected person.

The WHO removed the document from its database, claiming it was published in error, but screenshots of the study were leaked to the media. The manufacturer of remdesivir, pharmaceutical company Gilead Sciences, issued a statement that the publication contained “inappropriate study characteristics”.

“The study results are inconclusive, although other trials indicate potential benefits of remdesivir, especially for patients treated early in the course of the disease. A clear picture should be given by larger-scale studies that are being carried out now,”the representative of the pharmaceutical company emphasized.

Stephen Evans, a professor at the London School of Hygiene and Tropical Medicine, said the sample of study participants was too small to draw conclusions about the benefits or risks of the drug. However, he added that if a drug is effective only in the early stages of infection, its benefit may be much less than expected.

The antiviral drug remdesivir was one of the first to be used to treat COVID-19. In mid-April, Canadian scientists at the University of Alberta announced that the drug was effective in stopping the replication of the new coronavirus. Now in several countries, including Russia, its clinical trials are underway.

Popular by topic